STOCK TITAN
  1. Home
  2. Sec-filings
  3. KURA
  4. [Form 4] Kura Oncology, Inc. Insider Trading Activity

[Form 4] Kura Oncology, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Legal Officer Teresa Brophy Bair sold 2,256 shares of common stock in an open-market transaction at a weighted average price of $9.3795 per share. The sale was made under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025.

According to the filing, the 2,256 shares sold had been acquired on May 17, 2026 through the company’s Employee Stock Purchase Plan. Following this transaction, Bair directly holds 226,931 shares of Kura Oncology common stock.

Positive

  • None.

Negative

  • None.
Insider Bair Teresa Brophy
Role Chief Legal Officer
Sold 2,256 shs ($21K)
Type Security Shares Price Value
Sale Common Stock 2,256 $9.3795 $21K
Holdings After Transaction: Common Stock — 226,931 shares (Direct, null)
Footnotes (1)
  1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025. 2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan. This transaction was executed in multiple trades at prices ranging from $9.28 to $9.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Shares sold 2,256 shares Open-market sale of common stock on May 18, 2026
Weighted average sale price $9.3795 per share Multiple trades between $9.28 and $9.49
Shares held after transaction 226,931 shares Direct ownership following May 18, 2026 sale
Shares acquired via ESPP 2,256 shares Acquired May 17, 2026 under Employee Stock Purchase Plan
Rule 10b5-1 plan adoption date September 4, 2025 Plan governing the May 18, 2026 sale
Rule 10b5-1 trading plan regulatory
"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
weighted average sale price financial
"The price reported above reflects the weighted average sale price."
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Bair Teresa Brophy
(Last)(First)(Middle)
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Legal Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/18/2026S(1)2,256(2)D$9.3795(3)226,931D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 4, 2025.
2. 2,256 shares were acquired on May 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
3. This transaction was executed in multiple trades at prices ranging from $9.28 to $9.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
/s/ Teresa Bair05/20/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Kura Oncology (KURA) disclose for Teresa Brophy Bair?

Kura Oncology disclosed that Chief Legal Officer Teresa Brophy Bair sold 2,256 shares of common stock. The shares were sold in an open-market transaction at a weighted average price of $9.3795 per share, as detailed in the Form 4 filing.

At what price did the Kura Oncology (KURA) insider sale occur?

The reported insider sale occurred at a weighted average price of $9.3795 per share. The transaction was executed in multiple trades between $9.28 and $9.49, with the weighted average price disclosed as the transaction price in the Form 4.

How many Kura Oncology (KURA) shares does Teresa Brophy Bair hold after the sale?

After the reported sale, Teresa Brophy Bair directly holds 226,931 shares of Kura Oncology common stock. This post-transaction holding figure is provided in the Form 4 and reflects her remaining direct ownership following the 2,256-share disposition.

Was the Kura Oncology (KURA) insider sale under a Rule 10b5-1 plan?

Yes. The filing states the transaction was effected under a Rule 10b5-1 trading plan adopted on September 4, 2025. Such plans allow insiders to pre-schedule trades, helping separate trading decisions from subsequent market-sensitive information.

How were the 2,256 Kura Oncology (KURA) shares originally acquired before the sale?

The Form 4 notes that the 2,256 shares sold were acquired on May 17, 2026 through Kura Oncology’s Employee Stock Purchase Plan. This indicates the transaction involved shares obtained via the company’s employee share purchase program.

Who is the insider involved in the latest Kura Oncology (KURA) Form 4 filing?

The insider is Teresa Brophy Bair, who serves as Chief Legal Officer of Kura Oncology, Inc. She reported an open-market sale of 2,256 common shares and now directly owns 226,931 shares, according to the Form 4 disclosure.